Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$7.33 -0.8%	$8.65	$56.35 ▼ $105.00	$212.46M	0.95	12,438 shs	70,945 shs
IMNM Immunome	$9.94 -0.7%	$9.59	$5.15 ▼ $16.73	$865.18M	1.93	1.02 million shs	576,802 shs
MLYS Mineralys Therapeutics	$14.13 +4.2%	$14.11	$8.24 ▼ $18.38	$920.99M	-0.29	876,025 shs	1.24 million shs
URGN Urogen Pharma	$20.08 -0.1%	$14.91	$3.42 ▼ $21.01	$928.90M	1.12	1.58 million shs	953,432 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-0.14%	-6.93%	-24.75%	-2.12%	-87.93%
IMNM Immunome	+1.01%	-4.30%	+17.63%	+25.13%	-26.02%
MLYS Mineralys Therapeutics	+0.37%	+0.74%	-9.72%	-11.72%	+14.62%
URGN Urogen Pharma	+4.74%	+0.50%	+38.79%	+104.16%	+34.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	1.7498 of 5 stars	3.5	0.0	0.0	0.0	2.5	2.5	0.0
MLYS Mineralys Therapeutics	3.0158 of 5 stars	3.4	3.0	0.0	0.0	2.6	4.2	0.0
URGN Urogen Pharma	4.5617 of 5 stars	4.5	3.0	0.0	4.5	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
IMNM Immunome	3.00	Buy	$23.14	132.33% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	128.53% Upside
URGN Urogen Pharma	3.00	Buy	$31.43	56.28% Upside

Current Analyst Ratings Breakdown

Latest AVTE, URGN, MLYS, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
8/11/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $40.00
8/7/2025	IMNM Immunome	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$23.00 ➝ $22.00
8/7/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00
8/5/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
IMNM Immunome	$9.04M	95.91	N/A	N/A	$3.09 per share	3.22
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
URGN Urogen Pharma	$90.40M	10.29	N/A	N/A	($2.02) per share	-9.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
IMNM Immunome	-$292.96M	-$3.08	N/A	N/A	N/A	-1,687.08%	-76.10%	-65.14%	N/A
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-74.35%	-69.03%	N/A
URGN Urogen Pharma	-$126.87M	-$3.32	N/A	N/A	N/A	-164.44%	-97,487.15%	-59.38%	N/A

Latest AVTE, URGN, MLYS, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	-$0.66	+$0.12	-$0.66	N/A	N/A
8/7/2025	Q2 2025	URGN Urogen Pharma	-$0.82	-$1.05	-$0.23	-$1.05	$23.06 million	$24.22 million
8/6/2025	Q2 2025	IMNM Immunome	-$0.52	-$0.50	+$0.02	-$0.50	$1.03 million	$4.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
IMNM Immunome	N/A	12.13	12.13
MLYS Mineralys Therapeutics	N/A	26.48	26.48
URGN Urogen Pharma	N/A	4.14	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
IMNM Immunome	44.58%
MLYS Mineralys Therapeutics	84.46%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
IMNM Immunome	7.69%
MLYS Mineralys Therapeutics	25.56%
URGN Urogen Pharma	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
IMNM Immunome	40	87.04 million	80.35 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
URGN Urogen Pharma	200	46.26 million	44.09 million	Optionable

AVTE, URGN, MLYS, and IMNM Headlines

Recent News About These Companies

Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Brokerages

August 14 at 2:27 AM | marketbeat.com

17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners Ltd

August 13 at 7:06 AM | marketbeat.com

UroGen Pharma’s Earnings Call: Achievements and Challenges

August 13 at 2:04 AM | msn.com

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Buy" from Brokerages

August 13 at 2:29 AM | americanbankingnews.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript

August 12 at 4:03 PM | msn.com

HC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock Price

August 12 at 8:22 AM | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPS

August 11 at 2:33 PM | marketbeat.com

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

August 10, 2025 | finance.yahoo.com

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% on Disappointing Earnings

August 9, 2025 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak Earnings

August 8, 2025 | marketbeat.com

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...

August 8, 2025 | finance.yahoo.com

UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI

August 8, 2025 | tipranks.com

UroGen (URGN) Q2 Revenue Rises 11%

August 7, 2025 | aol.comA

UroGen (URGN) Q2 Revenue Rises 11%

August 7, 2025 | aol.comA

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7, 2025 | investing.com

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat

August 7, 2025 | investing.com

Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft

August 7, 2025 | tipranks.com

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVTE, URGN, MLYS, and IMNM Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$7.33 -0.06 (-0.81%)

As of 08/13/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Immunome NASDAQ:IMNM

$9.94 -0.07 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$9.95 +0.01 (+0.10%)

As of 04:41 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Mineralys Therapeutics NASDAQ:MLYS

$14.13 +0.57 (+4.20%)

Closing price 04:00 PM Eastern

Extended Trading

$14.14 +0.00 (+0.04%)

As of 06:18 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Urogen Pharma NASDAQ:URGN

$20.08 -0.03 (-0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$20.08 0.00 (0.00%)

As of 05:57 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time